SEC Form 4 · accession 0001144204-18-014729
ANI PHARMACEUTICALS INC · ANIP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur Przybyl
Officer — President and CEO · Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 7:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001023024
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 12, 2018 | M | 15,723 | $6.36 | A | 225,706 | D | |
| Common StockF1 | Mar 13, 2018 | S | 23,475 | $61.52 | D | 202,231 | D | |
| Common StockF2 | Mar 13, 2018 | S | 6,525 | $62.63 | D | 195,706 | D | |
| Common StockF3 | Mar 14, 2018 | S | 10,000 | $62.03 | D | 185,706 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF4 | $6.36 | Mar 12, 2018 | M | 15,723 | D | — | Jul 11, 2023 | Common Stock | 15,723 | 0 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $61.11 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $62.12 to $63.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $62.00 to $62.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013.